

**Table SII. Detailed presentation of laboratory adverse events**

CTCAE III-IV adverse event	Biologic	Occurrence (days)	Biologic regime altered	Comment
Neutropaenia	ADA	113	No	Once 0.6/nl, self-limited without treatment alteration.
Lymphocytopaenia	ADA	94	No	Once 0.2/nl, self-limited without treatment alteration.
	ADA	548	No	Once 0.3/nl, self-limited without treatment alteration.
Creatinine increase	ADA	274	No	Once 2.83 mg/dl, previously known chronic renal failure, baseline creatinine already at 2.34 mg/dl, concentration fell below CTCAE III° criteria without treatment alteration.
	ETA	28	No	Once 293 U/l, fell to normal limits without treatment alteration, no known cause.
GOT increase	ADA	77	No	Two measurements of 251 and 252 U/l within a week, fell to normal limits afterwards without treatment alteration, no known cause.
	ADA	85	Yes	Continuous increase to 239 U/l, previously known hemochromatosis, treatment cessation in good skin condition.
GPT increase	ADA	737	No	Once 239 U/l, concomitant MTX, fell to normal limits after cessation of MTX.
	ETA	531	No	Once 259 U/l, fell below 60 U/l without treatment alteration, no known cause.
GGT increase	ADA	15	No	Most GGT measurements above 200 U/l. S/p MTX. High alcohol intake.
	ADA	1,570	Yes	Once 325 U/l, subsequent diagnosis of hepatic metastases and treatment cessation.
	ETA	28	No	Repeatedly increased up to 904 U/l. 197 U/l at baseline. GPT max. 119 U/l, GOT max 101 U/l. S/p MTX. S/p alcohol abuse. HBV/HCV negative. Ultrasound and CT: hepatic steatosis. Liver biopsy refused. No known cause.
	ETA	28	No	Repeatedly increased up to 523 U/l, high alcohol intake.
	UST	57	No	Once 226 U/l, concomitant MTX, GGT dropped after reduction of MTX.
	UST	301	No	Repeatedly increased up to 402 U/l, high alcohol intake.

GOT: glutamate-oxaloacetate transaminase; GPT: glutamate-pyruvate transaminase; GGT: gamma-glutamyl transferase; ADA: Adalimumab; ETA: Etanercept; MTX: methotrexate; HBV/HCV: Hepatitis B virus/hepatitis C virus; S/p: status post.